- Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
- Data from Incyte’s Robust and Progressing Oncology Portfolio to be Presented at 2022 EHA Annual Meeting
- Incyte to Present at Upcoming Investor Conference
- Incyte Announces European Commission Approval of Jakavi® (ruxolitinib) as the First Post-Steroid Treatment for Acute and Chronic Graft-Versus-Host Disease
- Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs
- Incyte and Maruho Announce Strategic Alliance Agreement for Ruxolitinib Cream in Japan
- Incyte Announces Positive CHMP Opinion for Capmatinib (Tabrecta®) for the Treatment of METex14 Advanced Non-Small Cell Lung Cancer
- Incyte to Report First Quarter Financial Results
More ▼
Key statistics
On Friday, Incyte Corp (INCY:NSQ) closed at 77.67, -8.47% below its 52-week high of 84.86, set on Apr 08, 2022.
52-week range
Markit short selling activity
Open | 75.58 |
---|---|
High | 77.87 |
Low | 75.36 |
Bid | 65.15 |
Offer | 80.00 |
Previous close | 75.97 |
Average volume | 1.51m |
---|---|
Shares outstanding | 221.51m |
Free float | 218.09m |
P/E (TTM) | 18.49 |
Market cap | 17.20bn USD |
EPS (TTM) | 4.20 USD |
Data delayed at least 15 minutes, as of Jul 01 2022 21:00 BST.
More ▼